TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-80 years old~* Men or women~* Women post-menopausal or with ongoing contraception~* Diagnosis of acquired hemophilia A~* Patient must be insured~* Patient has provided written informed consent prior to enrollment~* Patient compliant~Exclusion Criteria:~* Congenital hemophilia~* Ongoing treatment with prednisone \> 20mg/d （or equivalent corticosteroid doses） more than 1 month~* Ongoing treatment with prednisone \>0.7mg/kg（or equivalent corticosteroid doses） more than 10 days~* Pregnant and breastfeeding women~* Allergy to steroid~* Immunosuppressive agents treatment within 30 days~* Serum transaminase and bilirubin greater than 1.5 times the upper limit of normal value~* Hepatitis B surface antigen or hepatitis C antibody or HIV antibody (I + II) or syphilis antibody positive~* Patients with diabetes, hypertension, glaucoma, peptic ulcer, herpes zoster, pulmonary infection and so on, who should not be treated with glucocorticoids~* Patients with poor compliance~* Those who can not take contraceptive measures during the test period~* Patient who is considered by the investigator not suitable for clinical study~* Thrombocytopenia~* Leucocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Steroid+Rituximab (Type: EXPERIMENTAL): Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.
- Steroid +Cyclophosphamide (Type: ACTIVE_COMPARATOR): Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* JIA subjects (male or female), ages 2-17 years with active disease who had an insufficient therapeutic response or intolerance to at least one non biologic DMARD or Tumor Necrosis Factor (TNFα) antagonists for at least 3 months prior to screening~* Subjects with TNFα inadequate response (or prior biologic) will be restricted to 30% of the population~* Subjects must have a history of at least 5 joints with active disease and must have currently active articular disease with ≥2 active joints and ≥2 joints with limitation of motion.~Exclusion Criteria:~* Subjects with other rheumatic diseases or major chronic inflammatory/immunologic diseases, active uveitis, systemic JIA with active systemic features (within a period of 6 months prior to enrollment), persistent Oligoarthritis JIA, or failed 3 or more TNFα antagonists or other biological DMARDs will be excluded.~* Active systemic disease: (ie, extra-articular features of systemic JIA including fever, rash, organomegaly) within a period of 6 months prior to randomization.~* Subjects who have failed more than two TNFα antagonists or other biologic DMARDs

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Short and Long Terms: Orencia (Type: EXPERIMENTAL): Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months~Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis: Subjects with a diagnosis of recurrent head and neck cancer~2. Based on clinical and radiographic evidence the tumor needs to be deemed resectable preoperatively~3. Age: Subjects must be ≥ 18 years of age and ≤ 90 years old~4. Informed Consent: All subjects must be able to comprehend and sign a written informed consent document~Exclusion Criteria:~1. Subjects who are pregnant or may become pregnant~2. Unresectable tumor~3. Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Cesium-131 Brachytherapy (Type: EXPERIMENTAL): Patients undergo brachytherapy using Cesium-131 during surgical resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~At time of diagnosis~* De novo multiple myeloma patients under 65 or in first relapse, in whom screening for chromosome 13 deletion and beta2microglobulin assay have been performed.~* Salmon and Durie Stage: III, II, I with symptomatic bone lesion (radiological)~* Patient's written informed consent~* No clinical signs of heart failure or coronary insufficiency with LVEF\>50%~* No hepatic in insufficiency: bilirubin\<35μmol/l and SGOT, SGPT, alkaline phosphatase less than 2.5 N~* No respiratory insufficiency: normal pulmonary function tests and DLCO\>50%~* No pre-existing renal impairment not related to the disease~* No history of any other malignant disease with the exception of basal cell carcinoma and stage I cervical cancer~* Negative HIV serology~* Effective contraception when justified~At the time of transplantation~* Good performance status (WHO score≤2)~* Creatinine≤170μmol/l and no ineligibility criteria for intensification~* Stem cells harvest ≥ 5x10E6 CD34/kg for 2 ASCT~* Absence of progressive disease before transplantation~Exclusion Criteria:~* Known refusal of the subject to participate to the study~* Female subject who is pregnant or breast-feeding~* History of allergy to any of the study medications, their analogues, or excipients in the various formulations~* Main liver insufficiency~* ≥ Grade 3 peripheral neuropathy on clinical examination within 14 days before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): bortézomib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Humoral Response to Tick-borne Encephalitis Vaccine in Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 years or more~* generally healthy~* no immunosuppressive condition~* fertile women must use contraceptives~Exclusion Criteria:~* Previous TBE infection~* Previously immunized with TBE vaccine~* Anaphylactic reaction to egg protein~* Any disease or therapy which might suppress the immune response~* Vaccination should be delayed if a participant has fever

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TBE vaccine at 0+30 days (Type: ACTIVE_COMPARATOR): This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
- TBE vaccine at 0+7+21 days (Type: ACTIVE_COMPARATOR): This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
- TBE vaccinte at 0+30+90 days (Type: ACTIVE_COMPARATOR): This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
- younger participants (Type: ACTIVE_COMPARATOR): This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of acute lymphoblastic leukemia (ALL) meeting 1 of the following criteria:~  * In first relapse after treatment~    * Has not yet received chemotherapy or radiotherapy for the first relapse~ * Primary refractory disease~* No mature B-cell ALL~* Meets criteria for one of the following risk groups:~  * Standard-risk disease: non-T-cell or T-cell ALL with late isolated extramedullary relapse~ * Intermediate-risk disease: non-T-cell ALL with early isolated extramedullary relapse or combined marrow and extramedullary relapse; non-T-cell ALL with late combined marrow and extramedullary relapse or isolated marrow relapse; or T-cell ALL with early isolated extramedullary relapse~ * High-risk disease: non-T-cell ALL with very early isolated extramedullary relapse, combined marrow and extramedullary relapse, or isolated marrow relapse; non-T-cell ALL with early isolated marrow relapse; T-cell ALL with very early isolated extramedullary relapse, combined marrow and extramedullary relapse, or isolated marrow relapse; T-cell ALL with early combined marrow and extramedullary relapse or isolated marrow relapse; or T-cell ALL with late combined marrow and extramedullary relapse or isolated marrow relapse~PATIENT CHARACTERISTICS:~* Not specified~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior bone marrow transplant

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (induction therapy) (Type: EXPERIMENTAL): Patients receive idarubicin IV over 1 hour on days 1 and 2; oral dexamethasone twice daily on days 1-5 and 15-19; intrathecal (IT) methotrexate on days 1 and 8; vincristine sulfate IV on days 3, 10, 17, and 24; and pegaspargase intramuscularly (IM) on days 3 and 17 or asparaginase IM on days 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25.
- Arm II (induction therapy) (Type: EXPERIMENTAL): Patients receive mitoxantrone IV over 1 hour on days 1 and 2. Patients also receive dexamethasone, methotrexate, vincristine sulfate, and pegaspargase or asparaginase as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinicopathological diagnosis of Waldenstrom's macroglobulinemia requiring therapy~* Baseline staging requirements~* Absolute Neutrophil Count \> 500/microliter (uL)~* Platelet Count \> 25,000/uL~* Serum creatinine \< 2.5mg/dL~* Total bilirubin and transaminase (SGOT) \< 2.5 X Upper Limit of Normal (ULN)~* Greater than 18 years of age~* Life expectancy of 3 months or greater~* Eastern Cooperative Oncology Group (ECOG) status performance of 0-2~Exclusion Criteria:~* Chemotherapy, steroid therapy, or radiation therapy within 30 days of study entry~* Pregnant or lactating women~* Serious co-morbid disease~* Uncontrolled bacterial, fungal or viral infection~* Active second malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Thalidomide and Rituximab (Type: EXPERIMENTAL): Thalidomide 200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks~Rituximab Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Urgency urinary incontinence or mixed urinary incontinence, established via telephone interview~* Urinary leakage twice a week or more often~* Duration of urinary leakage with urgency for at least 12 months~* Ability to read and write Swedish~* Asset to a smartphone (minimum iOS\* 8.0 for Apple, 4.0.3 for Androids~* Possibility to send and receive email and asset to printer~* Motivation and time to perform a 15 weeks long treatment programme with focus on self-care and behavioural training (mainly pelvic floor muscle training and bladder training).~* Accept to be randomized to one of two groups; a treatment app group or an information app Group~  * iOS=mobile operating system including iPhone, iPad and iPod touch~Exclusion Criteria:~* Participation in our previous internet or smartphone study~* Ongoing pregnancy~* Former incontinence surgery~* Known malignancy in lower abdomen~* Unassessed difficulties in emptying bladder~* Visual blood in urine~* Three or more urinary tract infections during the last 12 months~* One or more pyelonephritis during the last three years~* Painful micturition~* Painful urgency~* Intermenstrual bleeding~* Neurological disease such as multiple sclerosis or Parkinsons disease~* Previous stroke~* Diabetes mellitus~* Maximum voided volume of less than 150 ml (micturition chart)~* Regular use of any mobile app for pelvic floor muscle training during the last month~* Usage of antimuscarinic drugs or mirabegron during the last month

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Tät®II Treatment app (Type: EXPERIMENTAL): Comprehensive treatment programme with information and exercises. Individual advices.
- Tät®II Information app (Type: OTHER): Information only.~.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Ages between 18-45 years, inclusive~3. Non-tobacco/nicotine use (at least 3 months)~4. BMI of 17-35 kg/m2 inclusive~5. Able to comply with all study procedures and follow-up~6. Healthy on the basis of screening medical exam, blood chemistries, hematology, and serum pregnancy tests for females (at screening )~7. Non-pregnant or breast-feeding~Exclusion Criteria:~1. History of current use of narcotics, or recreational drug use.~2. Use of \> 7 alcoholic beverages in 1 week~3. Any acute illness such as asthma, cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal (including eating disorder), endocrine/metabolic, neurologic, dermatologic, or psychiatric disease.~4. Treatment with another investigational product in the past 30 days~5. Immunocompromised status including HIV by history~6. Use of any other intra-oral product (especially antiseptic).~7. Intended use of mouthwash during study duration~8. Laboratory (screening) of creatinine \> 1.5 X ULN, hemoglobin \< 10.5 g/dL, platelet count ≤ 99,000/mm3, absolute neutrophil count ≤1200/ mm3, serum glucose ≥ 150 mg/dl (Subject can enroll prior to receiving lab results. Subject will be contacted if lab results are an exclusion and discontinue from study)~9. Use of any systemic antibiotic or antifungal within 30 days of screening~10. Prior or current history of seasonal allergies, chronic sinusitis or rhinitis~11. Allergy to any component of Halo~12. Oral lesions~13. Dentures~14. Dental Treatment currently in progress (implants, root canals, complex restorative procedures)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Halo Oral Spray (Type: EXPERIMENTAL): Based upon the preliminary studies that assessed the duration of the antimicrobial effects of Halo as reported in the preliminary studies and feasibility, subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
- Halo Placebo (Type: PLACEBO_COMPARATOR): The placebo will consist of purified sterile water without CPC - the active antiseptic. Subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Omega 3 on Pregnancy Complicated by Asymmetrical Intrauterine Growth Restriction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: from 20 - 35 years old.~* Pregnant from 30 week to 32 week gestation.~* Singleton pregnancy with asymmetrical intrauterine growth restriction .~* Normal uterine and umbilical Doppler indices at time of recruitment.~Exclusion Criteria:~* Multiple gestations.~* Hypertensive women.~* Premature rupture of membranes.~* Abnormal Doppler indices in the form of Doppler blood flow indices \> 2 standard deviation , absent diastolic flow and lastly; reversed flow.~* Congenital fetal malformation.~* Pregnancy complicated by antepartum hemorrhage.~* Marked decrease in Amniotic fluid volume.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Low dose aspirin (Type: ACTIVE_COMPARATOR): Received aspirin 81mg once daily for 6 weeks
- Low dose aspirin plus omega 3 group (Type: ACTIVE_COMPARATOR): Received aspirin 81mg and omega 3 once daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have had a diagnosis of type 2 diabetes mellitus before screening.~* Participants who have been Oral Antihyperglycemic Medication (OAM)-naïve (diet and exercise only) or been taking OAM monotherapy except for thiazolidinedione (TZD) and are willing to discontinue this medication. Participants taking OAM monotherapy must complete 8-week washout period prior to randomization.~* Participants who are OAM naïve with a screening glycosylated hemoglobin (HbA1c) value of 7.0% to 10.0% and randomization HbA1c value of 7.0% to 10.0%, or who are taking OAM monotherapy with screening HbA1c value of 6.5% to 9.0% and randomization HbA1c value of 7.0% to 10.0%.~* Participants who have a body mass index (BMI) of 18.5 kilograms per meter squared (kg/m\^2) to 35.0 kg/m\^2.~Exclusion Criteria:~* Participants who have a diagnosis of type 1 diabetes.~* Participants who have previously been treated with any other glucagon-like peptide-1 (GLP-1) analog.~* Participants who have been receiving more than half of the maximum dose of sulfonylureas at screening.~* Participants who have been currently taking insulin or TZD, or have had previous insulin or TZD treatment within 3 months before screening.~* Participants who have obvious clinical signs or symptoms of pancreatitis, a history of chronic pancreatitis or acute pancreatitis at screening, as determined by the investigator. Participants who have a serum amylase concentration ≥3 times the upper limit of the reference range and/or a serum lipase concentration ≥2 times the upper limit of the reference range, as determined by the central laboratory at screening.~* Participants who have self or family history of medullary C-cell hyperplasia, focal hyperplasia, or medullary thyroid carcinoma (MTC).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2189265 (Type: EXPERIMENTAL): Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
- Placebo/LY2189265 (Type: PLACEBO_COMPARATOR): Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
- Liraglutide (Type: ACTIVE_COMPARATOR): Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete